except mine happened within hours. HIDEOUS swelling that gradually subsided over the next 5 days. So far it hasn\'t returned (injected mid June). The leftover restylane from the syringe i was injected with then turned watery and cloudy. The company seems to know what is going on, but is very tightlipped. On their website, they mention not to use and to contact them if material is cloudy, etc. I called and they won\'t tell me anything specific, and seemed very concerned re. liability.
I found the info below (and more) by googling "restylane hypersensitivity". I don\'t know for sure, but my best guess is that some batches are not washed as well as others, resulting in this bad reaction when it breaks down and releases the BDDE. Maybe your reaction ws delayed because it took that long to break down? I wonder if some kind of anti-inflammatory would help you.
Restylane, also known as NASHA (non-animal stabilized hyaluronic acid), is prepared in bacterial cultures of equine streptococci through fermentation in the presence of sugar. The product is then alcohol-precipitated, filtered and dried. Its crosslinked using a butanediol diglycidyl ether (BDDE) and then heat sterilized.
This highly crosslinked material forms a gel that is stiffer and harder than Hylaform. The stiffness of the product makes it much more difficult to wash out the crosslinking chemicals and residual bacterial proteins. The residual amount of the BDDE crosslinking substance that remains in the product is thought to lead to the inflammatory reactions reported with the use of Restylane and Perlane. The stiff, gel-like substance that results after washing and heating the modified HA is then broken into smaller pieces in a similar fashion as is Hylaform. The smallest pieces become the product Restylane Fine Line, the medium size particles become Restylane and the largest particles are packaged as Perlane.
There are two minor drawbacks to Restylane. The first is the presence of bacterial proteins in the resulting injectable product. Protein present in an injectable product can cause antibody formation to that protein with a subsequent allergic response. In a paper published in 2002 by Friedman, data from 144,000 patients injected with Restylane showed a hypersensitivity reaction in one of 1,400 patients treated in 1999. The same paper showed that one in every 5,000 patients treated in 2000 developed a hypersensitivity reaction. In 1999, a new formulation of Restylane was introduced that had a protein load 6-times lower than that found in the previous product. Since that time, hypersensitivity reactions have been said to decline.
The second issue of concern with Restylane is the remnants of the crosslinking agent that remain in the injectable product. Because the stiff gel is difficult to wash, byproducts of the crosslinking agent can remain in the product. Inflammation and swelling have often been described with the use of Restylane and its family members. A recent study comparing Perlane and Hylaform demonstrated an increased incidence of swelling in the Perlane group as compared to the Hylaform group. However, the bacterial origin of Perlane makes it cheaper and easier to produce than animal-derived products, such as Hylaform.